Rajesh Kumar Grover: Difference between revisions
>Monkbot m (Task 18 (cosmetic): eval 6 templates: hyphenate params (4×);) |
m (Removed empty portal template using script) |
||
| (One intermediate revision by one other user not shown) | |||
| Line 1: | Line 1: | ||
{{Short description|Indian oncologist}} | |||
{{Infobox person | {{Infobox person | ||
| name = Rajesh Kumar Grover | | name = Rajesh Kumar Grover | ||
| Line 34: | Line 35: | ||
==External links== | ==External links== | ||
* {{ResearchGate|Dr_Rajesh_K_Grover}} | * {{ResearchGate|Dr_Rajesh_K_Grover}} | ||
Latest revision as of 05:08, 14 August 2023
Rajesh Kumar Grover is an Indian oncologist and former director and chief executive officer of Delhi State Cancer Institute, New Delhi.[1][2] The Government of India honoured him, in 2014, with the award of Padma Shri, the fourth highest civilian award, for his contributions to the field of medicine.[3][4]
Rajesh Kumar Grover | |
|---|---|
| Born | India |
| Occupation | Oncologist |
| Awards | Padma Shri |
Dr Grover has over 50 scientific papers to his credit and has attended over 100 conferences and workshops in India and abroad. [1][2][3][4] Research Gate has published ten of his articles in their online repository.[5]
ReferencesEdit
- ↑ "Delhi State Cancer Institute". Delhi State Cancer Institute. 2014. Retrieved November 7, 2014.
- ↑ "India Medical Times". India Medical Times. 2014. Retrieved November 7, 2014.
- ↑ "Padma 2014". Press Information Bureau, Government of India. 25 January 2014. Retrieved October 28, 2014.
- ↑ "Drug Today". Drug Today. 2014. Retrieved November 7, 2014.
Further readingEdit
- Gargi Tikku; Dhruv Jain; Rajesh K Grover (October 2014). "Malignant proliferating trichilemmal tumor of the scalp masquerading as squamous cell carcinoma: A need for common awareness". Indian Journal of Pathology and Microbiology. 57 (4): 646–647. doi:10.4103/0377-4929.142705. PMID 25308032.
- R. K. Grover; Dhruv Jain (November 2014). "Re: Low Grade Micropapillary Urothelial Carcinoma, Does It Exist? – Analysis of Management and Outcomes from the Surveillance, Epidemiology and End Results (SEER) Database". European Urology. 66 (5): 967–968.